Australia markets closed

Sumitomo Pharma Co., Ltd. (DPM.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.9800+0.0300 (+1.54%)
At close: 08:02AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 805.26M
Enterprise value 3.07B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.42
Price/book (mrq)0.85
Enterprise value/revenue 1.65
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.54
52-week change 3-52.40%
S&P500 52-week change 323.76%
52-week high 34.3200
52-week low 31.6400
50-day moving average 32.1436
200-day moving average 32.6086

Share statistics

Avg vol (3-month) 341
Avg vol (10-day) 330
Shares outstanding 5397.29M
Implied shares outstanding 6406.69M
Float 8179.4M
% held by insiders 157.59%
% held by institutions 116.53%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.09
Forward annual dividend yield 43.73%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 42.25
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 430 Mar 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -100.13%
Operating margin (ttm)-298.49%

Management effectiveness

Return on assets (ttm)-21.74%
Return on equity (ttm)-111.89%

Income statement

Revenue (ttm)314.56B
Revenue per share (ttm)791.76
Quarterly revenue growth (yoy)-16.50%
Gross profit (ttm)N/A
EBITDA -317.37B
Net income avi to common (ttm)-314.97B
Diluted EPS (ttm)-4.7000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)29.05B
Total cash per share (mrq)73.11
Total debt (mrq)418.88B
Total debt/equity (mrq)268.28%
Current ratio (mrq)0.52
Book value per share (mrq)392.82

Cash flow statement

Operating cash flow (ttm)-241.89B
Levered free cash flow (ttm)-256.89B